Longevity Acquisition Corporation
Status: Deal Closed
U=S+W+R
W=S/2@11.5
R=S/10
| IPO Proceeds, $M | $40.00M |
|---|---|
| IPO Date | Aug 29, 2018 |
| CEO | Matthew Chen |
| Left Lead | Cantor Fitzgerald |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 12+3+3+3+6+6 |
| IPO Sector |
General
China |
| IPO Geography | Asia |
| Target Company | 4D Pharma |
| Deal Announced | Oct 22, 2020 |
| Deal Size, $M | $184.40M |
| Deal Sector | Healthcare |
| Deal Geography | Asia |
| SEC Filings | www.sec.gov |
| Approval Vote | Mar 17, 2021 |
| Amendment Vote | TBD |
| Closing Date | Mar 19, 2021 |
Formerly LOAC
LBPS
LBPSW
| Price | $0.00 |
|---|---|
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Longevity Acquisition Corporation:
- Structure and cap table
- 6 directors & officers
- 36 filings and events
- 1 underwriters
- 1 deal advisors
- 5 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Matthew Chen | 46 | Chairman & CEO |
| Teddy Zheng | 35 | CFO |
| Pai Liu | 34 | Director |
| Jun Liu | 47 | Director |
| Yukman Lau | 65 | Director |
| Bill Huo | Advisor |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Cantor Fitzgerald | BR | 4,000,000 | units |
| 4,000,000 | units | ||
| Up-Front UW fee | 3.00 | % | |
| Deferred UW fee |
2.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.